Asthma therapy may become ineffective in part because of desensitization
of the beta2-adrenergic response by continued treatment with beta2-
agonist. Desensitization of the beta2-adrenergic receptor (beta2AR) will
be studied as a model for the regulation of 7-membrane spanning G-protein
coupled receptors, and for the regulated endocytosis of signalling
receptors generally. Desensitization occurs by several distinct
mechanisms. Within seconds of agonist binding, receptor is phosphorylated
and uncouples from G-S. Within minutes of binding, sequestration of
receptors occurs by internalization into an endocytic compartment.
Sequestered receptors probably are resensitized before they return to the
surface. Chronic exposure to agonist (hours) causes the loss of cellular
receptor (down-regulation), and may occur by both lysosomal receptor
degradation and decreased receptor synthesis. The goal of this proposal is
to use small GTPases of the rab family, that regulate the endocytosis of
surface receptors, to discover the molecular mechanisms of beta2AR
sequestration and recycling. The working hypothesis is that rab GTPases
are required for the regulation of the beta2AR by causing an alteration in
its cellular distribution in response to agonist. Small GTPases such as
rabs are molecular switches that bind and hydrolyze GTP, then dissociate
from GDP in a regulated shuttle between two activity states. rab4 and rab5
are associated with the endocytic compartment and may play a role in the
accurate direction of vesicle traffic. These studies will determine the
roles of rab4 and rab5 in the trafficking of the human beta2AR, and
discover other proteins involved in this process. Wild-type rab4 and rab5,
and their dominant suppressive mutations, will be overexpressed in a cell
line that expresses an epitope-tagged human beta2AR. Changes in receptor
sequestration caused by rab5 overexpression will be studied using
radioligand binding assays in whole cells and in membrane fractions, and
by immunofluorescence with laser confocal microscopy. Changes in recycling
and resensitization will be measured after overexpression of rab4. Other
components of the endocytic apparatus will be identified as proteins that
interact with rab5 using a genetic assay in yeast, and then characterized
biochemically and by subcellular localization. These studies will clarify
the intracellular trafficking of beta2AR and the regulatory roles of rab
proteins in that process. In addition, components of the endocytic machine
will be identified, leading to the potential for developing therapeutics
based on regulating the endocytosis of beta2AR.
No Sub Projects information available for 1R01HL050047-01A2
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01HL050047-01A2
Patents
No Patents information available for 1R01HL050047-01A2
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01HL050047-01A2
Clinical Studies
No Clinical Studies information available for 1R01HL050047-01A2
News and More
Related News Releases
No news release information available for 1R01HL050047-01A2
History
No Historical information available for 1R01HL050047-01A2
Similar Projects
No Similar Projects information available for 1R01HL050047-01A2